Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, Inka (Institut d'Investigació Biomèdica Sant Pau)
Pérez Pérez, Antonio (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona

Data:	2017
Resum:	Several GLP-1 receptor agonists are currently available for treatment of type 2 diabetic patients. Based on their pharmacokinetic/pharmacodynamic profile, these drugs are classified as short-acting GLP-1 receptor agonists (exenatide and lixisenatide) or long-acting GLP-1 receptor agonists (exenatide-LAR, liraglutide, albiglutide, and dulaglutide). In clinical practice, they are also classified as basal or prandial GLP-1 receptor agonists to differentiate between patients who would benefit more from one or another based on characteristics such as previous treatment and the predominance of fasting or postprandial hyperglycemia. In the present article we examine available data on the pharmacokinetic characteristics of the various GLP-1 agonists and compare their effects with respect to the main parameters used to evaluate glycemic control. The article also analyzes whether the differences between the different GLP-1 agonists justify their classification as basal or prandial.
Nota:	Altres ajuts: IM has received consultancy fess or lecture honoraria from Boerhinger Ingelheim, Eli Lilly, MSD, Novo Nordisk, Sanofi-Aventis and Astra-Zeneca and has participated in clinical trials funded by Sanofi-Aventis. AP has received consultancy fess or lecture honoraria from GSK, Boerhinger Ingelheim, Eli Lilly, Menarini, Merk, MSD, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, AstraZeneca, Almirall and Esteve and has participated in clinical trials funded by GSK, Sanofi-Aventis, Almirall, Esteve.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Type 2 diabetes mellitus ; Glycemic control ; Postprandial glycemia ; GLP-1 receptor agonists
Publicat a:	Diabetology & Metabolic Syndrome, Vol. 9 (january 2017) , ISSN 1758-5996

DOI: 10.1186/s13098-017-0204-6
PMID: 28115994

9 p, 847.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats